Clinical trial design in oncology

Lancet Oncology

Volumn 5, Issue 12, 2004, Pages 759-763

  Sullivan, Richard ^a   Fey, Matin F ^b   Gallo, Ciro ^c   Perrone, Francesco ^d   Gebski, Val ^e  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL;

ACCURACY; ARTICLE; CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; DRUG SURVEILLANCE PROGRAM; EXPERT SYSTEM; GOOD CLINICAL PRACTICE; HEALTH CARE POLICY; HUMAN; METHODOLOGY; ONCOLOGY; OUTCOMES RESEARCH; PATIENT SELECTION; PILOT STUDY; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; QUALITY OF LIFE; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT FAILURE; UNITED KINGDOM; UNITED STATES;

EID: 10644252710     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01654-7     Document Type: Note

References (39)

1. International Conference on Harmonisation. ICH-E6. Good clinical practice and consolidated guide. Section 6. CPMP/ICH/135/95, 1997
2. Altman DG Schulz KF Moher D et al. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration Ann Int Med 134 2001 663-694
3. Newell DR Searle KM Westwood NB Burtles SS. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK Br J Cancer 89 2003 437-454
4. Aapro MS. Geriatric oncology: A long way to go? Crit Rev Oncol Hematol 48 2003 101
5. Corrie P Shaw J Harris R. Rate limiting factors in recruitment of patients to clinical trials in cancer research: Descriptive study BMJ 327 2003 320-321
6. International Conference on Harmonisation. ICH-9. Statistical principles for clinical trials. CPMP/ICH/383/96, 1998
7. Thezenas S Duffour J Coline S Kramar A. Five-year change in statistical designs of phase II trials published in leading cancer journals Eur J Cancer 40 2004 1244-1249
8. Johnson JR et al. Endpoints and US FDA approval of oncology drugs J Clin Onc 7 2003 1404-1411
9. UK Department of Health and UK Medical Research Council. http://www.ct-toolkit.ac.uk (accessed Nov 2, 2004)
10. Mengis C Aebi S Tobler A et al. Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukaemia trials J Clin Oncol 21 2003 3933-3939
11. Feinstein AR Sosin DM Wells CK. The Will Rogers Phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer New Engl J Med 312 1985 1604-1608
12. Yusuf S Collins R Peto R. Why do we need some large, simple randomised trials? Statistics Med 3 1984 409-420
13. Arriagada R Bergamn B Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer New Engl J Med 350 2004 351-360
14. Sauter C. Adjuvant chemotherapy for lung cancer New Engl J Med 350 2004 1681
15. Dunant A Pignon JP le Chevalier T. Adjuvant chemotherapy for lung cancer N Engl J Med 350 2004 1682-1683
16. International Collaborative Ovarian Neoplasm (ICON) Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin, or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial Lancet 360 2002 505-515
17. Ozols RF Markman M Thigpen TJ. ICON3 and chemotherapy for ovarian cancer Lancet 360 2002 2086
18. Holmberg L Baum M. Can results from clinical trials be generalized? Nature Med 1 1995 734-736
19. Breathnach OS Freidlin B Conley B et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results J Clin Oncol 19 2001 1734-1742
20. Sackett DL. Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!) CMAJ 165 2001 1226-1237
21. Girling DJ Parmar MKB Stenning SP et al. Clinical trials in cancer: principles and practice 2003 Oxford University Press Oxford
22. Moher D Schulz KF Altman DG Schulz for the CONSORT Group The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials.? Lancet 357 2001 1191-1194
23. Goodman SN Berlin J. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results Ann Int Med 121 1994 200-206
24. Freedman LS. The size of clinical trials in cancer research-what are the current needs? Br J Cancer 59 1989 396-400
25. Horrobin DF. Are large clinical trials in rapidly lethal diseases usually unethical? Lancet 361 2003 695-697
26. Halpern SD Karlawish JHT Berlin JA. The continuing unethical conduct of underpowered clinical trials JAMA 288 2002 358-362
27. Krzyzanowska MK Pintilie M Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting JAMA 290 2003 495-501
28. Cannistra SA. The ethics of early stopping rules: Who is protecting whom? J Clin Oncol 9 2004 1542-1545
29. Sandler R Halabi S BaronJ et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 338 2003 883-890
30. Therasse P Arbuck S Eisenhauer E et al. New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 2000 205-216
31. Gray B Van Hazel G Hope M et al. Randomised trial of SIR-spheres plus chemotherapy alone for treating patients with liver metastases from primary large bowel cancer Ann Oncol 12 2001 1711-1720
32. Caplan R Pajak T Cox J. Analysis of the probability and risk of cause specific failure Int J Radiat Oncol Biol Phys 29 1994 1183-1186
33. Gooley T Leisenring W Crowley J Storer B. Why Kaplan-Meier fails and cumulative incidence succeeds when estimating probabilities in the presence of competing risks. In: Crowley J (Ed.). Handbook of statistics in clinical oncology 2001 Marcel Dekker New York
34. The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf (accessed Nov 2, 2004)
35. Buyse M Thirion P Carlson R et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis Lancet 356 2000 373-377
36. Bernhard J Gelber R. Workshop on missing data in quality of life research in cancer clinical trials: Practical and methodological issues Stat Med 17 1998 511-651
37. Gelber R Cole B Gelber S Goldhirsch A. The Q-TWiST method. In: Spilker B (Ed.). Quality of kife and pharmacoeconomics in clinical trials 2nd edn 1996 437-444 Lippincott-Raven Philadelphia
38. Ellis M Ballman K. Trawling for genes that predict response to breast cancer adjuvant therapy J Clin Oncol 22 2004 1-3
39. Ayers M Symmans W Stec J. et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 15 2004 2284-2293